Zoetis traded at $118.21 this Tuesday March 31st, increasing $1.88 or 1.62 percent since the previous trading session. Looking back, over the last four weeks, Zoetis gained 8.34 percent. Over the last 12 months, its price fell by 26.99 percent. Looking ahead, we forecast Zoetis to be priced at 109.95 by the end of this quarter and at 100.35 in one year, according to Trading Economics global macro models projections and analysts expectations.
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.